Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | NPY4R | P50391 | 11/20 | 0.43 |
| ▸ | NPY1R | P25929 | 8/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.43 |
| ▸ | NPY2R | P49146 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8720811 | 1.00 | MAPK8 (0.44) | MAPK8MAPK9MAPK10NPY4RNPY1R | |
| SCHEMBL30974427 | 0.96 | KDM1A (0.43) | MAPK8MAPK9MAPK10NPY4RNPY1R | |
| SCHEMBL29687469 | 0.96 | MAPK8 (0.48) | MAPK8MAPK9MAPK10NPY4RNPY1R | |
| SCHEMBL29437943 | 0.96 | MAPK8 (0.43) | MAPK8MAPK9MAPK10NPY4RNPY1R | |
| SCHEMBL29496543 | 0.92 | MEN1 (0.44) | MAPK8MAPK9MAPK10MEN1KMT2A | |
| SCHEMBL29825310 | 0.92 | MAPK8 (0.44) | MAPK8MAPK9MAPK10NPY4RNPY1R | |
| SCHEMBL29663559 | 0.92 | MAPK8 (0.46) | MAPK8MAPK9MAPK10NPY4RNPY1R | |
| SCHEMBL31097677 | 0.92 | KDM1A (0.47) | MAPK8MAPK9MAPK10NPY4RNPY1R | |
| SCHEMBL31097702 | 0.92 | KDM1A (0.47) | MAPK8MAPK9MAPK10NPY4RNPY1R | |
| SCHEMBL31239106 | 0.92 | KDM1A (0.47) | MAPK8MAPK9MAPK10NPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2025-12-18 | — | — | US | disclosed |
| CN-120694407-A | Tripeptide-chlorogenic acid synergistic antioxidant compound and application thereof | 重庆大学 | 2025-09-26 | — | — | CN | disclosed |
| EP-4608437-A2 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | Barinthus Biotherapeutics North America, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250242015-A1 | SELF-ASSEMBLING NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2025-07-31 | — | — | US | disclosed |
| US-12370255-B2 | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250127887-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-20240269269-A1 | Self-Assembling Nanoparticles | VACCITECH NORTH AMERICA, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| CN-118103059-A | Self-assembled nanoparticles based on amphiphilic peptides | 巴林萨斯生物疗法北美公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2024092028-A2 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | VACCITECH NORTH AMERICA, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-4294431-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES | Vaccitech North America, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2022177993-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES | VACCITECH NORTH AMERICA, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| EP-0570244-B1 | Process for preparing peptides having a C-terminal proline amide | SANKYO CO (JP) | 1998-02-11 | — | — | EP | disclosed |
| EP-0570244-A1 | Process for preparing peptides having a c-terminal proline amide | SANKYO COMPANY LIMITED (JP) | 1993-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127887-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | IAPP, BRCA1, ANXA11 | MAPK8 3032/4885MAPK9 2940/4885MAPK10 2072/4885 |
| US-20240269269-A1 | Self-Assembling Nanoparticles | UBE2B, CD4, UBE2G2 | MAPK8 2073/4885MAPK9 3209/4885MAPK10 3137/4885 |
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | IL2, IFNG, ICOS | MAPK8 2621/4885MAPK9 3231/4885MAPK10 885/4885 |
| US-20250242015-A1 | SELF-ASSEMBLING NANOPARTICLES | UBE2B, CD4, HRH1 | MAPK8 2094/4885MAPK9 3243/4885MAPK10 3181/4885 |
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | VIP, HM13, SPPL2B | MAPK8 2911/4885MAPK9 2423/4885MAPK10 1588/4885 |
| US-12370255-B2 | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response | MYD88, ICOS, CD4 | MAPK8 1612/4885MAPK9 967/4885MAPK10 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.